CDMO - Avid Bioservices, Inc.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
24%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 24.12%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -11.94%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.5
Debt Ratio is 0.56
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations turning Positive
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Avid Bioservices, Inc. (CDMO) - http://avidbio.com
Avid Bioservices, Inc. engages in the commercial manufacturing which focuses on biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. The firm specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions, and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Nicholas S. Green
Employees - 222
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.